17:47 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Antibe's pain candidate meets in Phase IIb GI safety trial

Antibe Therapeutics Inc. (TSX-V:ATE; OTCQX:ATBPF) reported data from a double-blind, Canadian Phase IIb trial in 244 healthy volunteers undergoing gastroduodenal endoscopies showing that pain candidate ATB-346 for 14 days met the primary endpoint of improved...
23:29 , Oct 6, 2017 |  BioCentury  |  Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
21:28 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

Antibe starts Phase II trial of ATB-346 in healthy volunteers

Antibe Therapeutics Inc. (TSX-V:ATE; OTCQX:ATBPF) began a Phase II trial of pain candidate ATB-346 in healthy volunteers. The double-blind, placebo-controlled trial will evaluate once-daily 250 mg ATB-346 for 14 days vs. naproxen sodium in 240...
22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
19:41 , Jun 23, 2017 |  BC Week In Review  |  Financial News

Antibe closes C$4 million follow-on

On June 21, pain and inflammation company Antibe Therapeutics Inc. (TSX-V:ATE; OTCQX:ATBPF) raised C$4 million ($3.1 million) through the sale of 40.5 million units at C$0.10 in the first close of a follow-on. Bloom Burton,...
18:33 , May 26, 2017 |  BC Week In Review  |  Financial News

Antibe amends follow-on

On May 26, pain and inflammation company Antibe Therapeutics Inc. (TSX-V:ATE; OTCQX:ATBPF) amended its follow-on to raise up to C$5 million ($3.7 million), saying it would offer each unit at C$0.10. Bloom, Dominick and Echelon...
20:36 , Jan 6, 2017 |  BC Week In Review  |  Financial News

Antibe completes private placement

Antibe raised C$297,750 ($222,002) through the sale of 2 million units at C$0.15 in the second and final tranche of a private placement, bringing the total raised to C$2.7 million ($2.1 million). Each unit comprises...
00:41 , Dec 21, 2016 |  BC Week In Review  |  Financial News

Antibe completes private placement

Antibe raised C$2.4 million ($1.8 million) through the sale of 16.2 million units at C$0.15 in the first tranche of a planned C$3 million ($2.2 million) private placement. Each unit comprises a share and a...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

ATB-346: Phase II data

An open-label, Canadian Phase II trial in 12 patients with OA of the knee showed that once-daily 250 mg oral ATB-346 reduced Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score by 4.3 points...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Financial News

Antibe Therapeutics completes private placement of units

Antibe Therapeutics Inc. (TSX-V:ATE; OTCQX:ATBPF), Hamilton, Ontario   Business: Neurology, Autoimmune, Endocrine/Metabolic   Date completed: 2016-06-20   Type: Private placement of units   Raised: C$486,500 ($378,935)   Units: 4.9 million   Price: C$0.10 (unit)  ...